Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Vistagen Therapeutics (VTGN) Shares Outstanding (Diluted Average) (2023 - 2025)

Vistagen Therapeutics' Shares Outstanding (Diluted Average) history spans 9 years, with the latest figure at $36.7 million for Q4 2025.

  • For Q4 2025, Shares Outstanding (Diluted Average) rose 19.35% year-over-year to $36.7 million; the TTM value through Dec 2025 reached $36.7 million, up 19.35%, while the annual FY2025 figure was $30.9 million, 59.53% up from the prior year.
  • Shares Outstanding (Diluted Average) for Q4 2025 was $36.7 million at Vistagen Therapeutics, up from $35.7 million in the prior quarter.
  • Across five years, Shares Outstanding (Diluted Average) topped out at $36.7 million in Q4 2025 and bottomed at $7.3 million in Q2 2023.
  • The 3-year median for Shares Outstanding (Diluted Average) is $30.6 million (2024), against an average of $25.3 million.
  • The largest annual shift saw Shares Outstanding (Diluted Average) skyrocketed 317.11% in 2024 before it grew 4.34% in 2025.
  • A 3-year view of Shares Outstanding (Diluted Average) shows it stood at $15.6 million in 2023, then skyrocketed by 96.46% to $30.7 million in 2024, then grew by 19.35% to $36.7 million in 2025.
  • Per Business Quant, the three most recent readings for VTGN's Shares Outstanding (Diluted Average) are $36.7 million (Q4 2025), $35.7 million (Q3 2025), and $31.9 million (Q2 2025).